MRUS241220C30000
- 17.90
- 0.000.00%
Merus Newsroom
Merus Power Completes Major Battery Energy Storage System Project in Finland
Buy Rating for Merus: Promising Pipeline and Competitive Advantage of Petosemtamab
Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Pyxis Stock Craters 46% Amid Phase 1 Data, William Blair Downgrade
Goldman Sachs Initiates Merus(MRUS.US) With Buy Rating, Announces Target Price $73
Needham Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $85
Truist Financial Initiates Merus(MRUS.US) With Buy Rating
Merus Price Target Maintained With a $85.00/Share by Needham
Merus's Stock Poised for Growth Amidst Promising Data and Market Positioning
EQT Life Sciences Leads €54 Million Series A Financing of ATB Therapeutics
Catalyst Watch: Nvidia Earnings, Microsoft Ignite, Crypto Confidence, and P&G Event
Vaccinex Announces Signing Of Proprietary Project Agreements With Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ThirdArc And Incyte To Employ Vaccinex's ActivMAb Technology
Merus to Present at Upcoming Investor Conferences
CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Fresenius Medical Care (FMS) and Treace Medical Concepts (TMCI)
Express News | U.s-Listed Shares of Merus NV Down 4.5% After FDA Extends Review of Co's Gene-Targeting Cancer Therapy
Merus Receives FDA Extension of PDUFA for Zenocutuzumab
Merus's Promising Pipeline and Financial Strength Support Buy Rating
While Merus (NASDAQ:MRUS) Shareholders Have Made 214% in 5 Years, Increasing Losses Might Now Be Front of Mind as Stock Sheds 4.8% This Week